Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2019-01-28 Transaction in Own Shar…
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 95% confidence The document is a press release dated January 28, 2019, announcing that a block of 1,400,000 shares (15.32% of capital) was acquired by certain managers, employees, and the company itself as part of a share repurchase program. This involves transactions in the company's own shares by insiders and the company itself. While it mentions management strengthening their stake, the core event is the transaction of shares. This aligns most closely with the 'Transaction in Own Shares' (POS) category, which covers share repurchases or issuance. It is not a Director's Dealing (DIRS) as it involves the company buying shares and a collective management purchase, not just individual director trades, although management is involved. Since the primary action is the company buying back shares, POS is the best fit. The document is short and is a direct announcement, not a regulatory filing form itself.
2019-01-28 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document is titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and presents key financial highlights for the year 2018, specifically the 'Chiffre d'affaires 2018' (2018 Revenue). It provides summarized, non-audited figures and discusses business segments and outlook. Crucially, it explicitly states: 'Prochaine publication : Résultats annuels 2018, le 18 avril 2019, après Bourse.' (Next publication: Annual results 2018, April 18, 2019, after market close). Since this document only announces preliminary results and points to a future, more comprehensive filing (the Annual Results, likely a 10-K or IR), it fits the definition of an initial announcement of periodical financial results. This aligns perfectly with the Earnings Release (ER) definition, which covers the initial announcement of periodical financial results (key highlights only). It is too brief and preliminary to be classified as a full Annual Report (10-K) or Interim Report (IR). FY 2018
2019-01-18 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a press release ("Communiqué de presse") dated January 14, 2019, titled "Calendrier financier 2019" (2019 Financial Calendar). It explicitly lists future dates for key financial publications, such as 2018 revenue ('Chiffre d'affaires 2018') and 2018 annual results ('Résultats annuels 2018'). This document is not the actual financial report (like 10-K or IR) but an announcement detailing *when* those reports will be released. According to Rule 2 (The 'Menu vs Meal' Rule), a short announcement about the publication timing of reports falls under Report Publication Announcement (RPA). The document length (2257 chars) supports this being an announcement rather than a full report.
2019-01-14 French
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 99% confidence The document is a press release dated June 11, 2018, detailing the 'Rachat d'un bloc de 51 500 titres hors marché' (Buyback of a block of 51,500 shares off-market). This action involves the company acquiring its own shares, which directly corresponds to the definition of 'Transaction in Own Shares'. The document explicitly states the number of shares bought back, the price, and the purpose (to cover stock option plans and free share allocations). This fits the 'Transaction in Own Shares' category (POS) perfectly, rather than a general financing update (CAP) or a major shareholding notification (MRQ), as it is the company itself executing the transaction.
2018-06-11 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a press release ("Communiqué de presse") dated January 9, 2018, detailing the company's financial calendar for 2018. It announces the future dates for the release of 2017 revenue, 2017 annual results, and 2018 half-year figures. Since the document itself is an announcement about the *timing* of future financial reports (like annual results and revenue updates) rather than the reports themselves, it fits the definition of a Report Publication Announcement (RPA). The document is short (2163 characters) and its primary function is to communicate when other reports will be released, aligning with the 'MENU VS MEAL' rule.
2018-01-09 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated November 23, 2017, announcing that Biosynex won two awards from the Deloitte In Extenso Technology Fast 50 ranking (Biotech & Life Science and best Euronext growth). It details the criteria (revenue growth between 2013 and 2016) and includes quotes from the CEO and a Deloitte partner. Crucially, it concludes with a 'Prochaine publication' (Next publication) notice: 'Chiffre d'affaires annuel 2017 : le 25 janvier 2018 après bourse' (Annual revenue 2017: January 25, 2018 after market close). This document is an announcement about an award and a future reporting date, not the actual financial report (like 10-K or IR) or a standard earnings release (ER). Since it is a general press release announcing company news (awards) and does not fit into specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), as press releases often fall here when not otherwise specified, or it could be considered a general announcement. Given the options, RNS (Regulatory Filings) is the best fit for a general, non-mandatory regulatory announcement that isn't a specific financial report or management change.
2017-11-23 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.